Next Article in Journal
Ontogenetic Pattern Changes of Nucleobindin-2/Nesfatin-1 in the Brain and Intestinal Bulb of the Short Lived African Turquoise Killifish
Next Article in Special Issue
Prognostic Significance of Glucose Metabolism as GLUT1 in Patients with Pulmonary Pleomorphic Carcinoma
Previous Article in Journal
Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy
Previous Article in Special Issue
Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 9
Issue 1
10.3390/jcm9010102
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer

by
Yuki Katayama
1,†,
Takayuki Shimamoto
1,†,
Tadaaki Yamada
1,*,
Takayuki Takeda
2,
Takahiro Yamada
3,
Shinsuke Shiotsu
4,
Yusuke Chihara
5,
Osamu Hiranuma
6,
Masahiro Iwasaku
1,
Yoshiko Kaneko
1,
Junji Uchino
1 and
Koichi Takayama
1
1
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
2
Department of Pulmonary Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto 602-8026, Japan
3
Department of Pulmonary Medicine, Matsushita Memorial Hospital, Moriguchi 570-8540, Japan
4
Department of Pulmonary Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan
5
Department of Pulmonary Medicine, Uji-Tokushukai Medical Center, Uji 611-0041, Japan
6
Department of Pulmonary Medicine, Otsu City Hospital, Otsu 520-0804, Japan
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work and share first authorship.
J. Clin. Med. 2020, 9(1), 102; https://doi.org/10.3390/jcm9010102
Submission received: 9 December 2019 / Revised: 19 December 2019 / Accepted: 29 December 2019 / Published: 31 December 2019
(This article belongs to the Special Issue Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments)
Browse Figures
Versions Notes

Abstract

Little is known regarding the effectiveness and tolerability of immune checkpoint inhibitor (ICI) rechallenge after disease progression following initial ICI treatments. To identify eligible patients for ICI rechallenge, we retrospectively analyzed the relationship between clinical profiles and the effect of ICI rechallenge in patients with non-small cell lung cancer (NSCLC). We enrolled 35 NSCLC patients at six different institutions who were retreated with ICIs after discontinued initial ICI treatments due to disease progression. Cox proportional hazards models were used to assess the impact of clinical profiles on overall survival (OS) and progression-free survival (PFS). Median PFS and OS were 81 d (95% confidence interval, CI, 41–112 d) and 225 d (95% CI 106–361 d), respectively. The objective response rate was 2.9%, and the disease control rate was 42.9%. Multivariate analysis demonstrated that Eastern Cooperative Oncology Group Performance Score (ECOG-PS) ≥ 2 (hazard ratio, HR, 2.38; 95% CI 1.03–5.52; p = 0.043) and body mass index (BMI) > 20 (HR 0.43, 95% CI 0.19–0.95, p = 0.036) were significantly associated with PFS of ICI rechallenge. Our observations suggest that poor ECOG-PS and low BMI at intervention with ICI rechallenge may be negative predictors for ICI rechallenge treatment in patients with NSCLC.
Keywords: immunotherapy; rechallenge; non-small cell lung cancer; retrospective analysis immunotherapy; rechallenge; non-small cell lung cancer; retrospective analysis

Share and Cite

MDPI and ACS Style

Katayama, Y.; Shimamoto, T.; Yamada, T.; Takeda, T.; Yamada, T.; Shiotsu, S.; Chihara, Y.; Hiranuma, O.; Iwasaku, M.; Kaneko, Y.; et al. Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. J. Clin. Med. 2020, 9, 102. https://doi.org/10.3390/jcm9010102

AMA Style

Katayama Y, Shimamoto T, Yamada T, Takeda T, Yamada T, Shiotsu S, Chihara Y, Hiranuma O, Iwasaku M, Kaneko Y, et al. Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. Journal of Clinical Medicine. 2020; 9(1):102. https://doi.org/10.3390/jcm9010102

Chicago/Turabian Style

Katayama, Yuki, Takayuki Shimamoto, Tadaaki Yamada, Takayuki Takeda, Takahiro Yamada, Shinsuke Shiotsu, Yusuke Chihara, Osamu Hiranuma, Masahiro Iwasaku, Yoshiko Kaneko, and et al. 2020. "Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer" Journal of Clinical Medicine 9, no. 1: 102. https://doi.org/10.3390/jcm9010102

APA Style

Katayama, Y., Shimamoto, T., Yamada, T., Takeda, T., Yamada, T., Shiotsu, S., Chihara, Y., Hiranuma, O., Iwasaku, M., Kaneko, Y., Uchino, J., & Takayama, K. (2020). Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 9(1), 102. https://doi.org/10.3390/jcm9010102

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop